News & Updates
Filter by Specialty:
Assisted reproductive technology poses no excess risk of multiple sclerosis
Exposure to assisted reproductive technology (ART) does not appear to promote the development of multiple sclerosis, a study has found.
Assisted reproductive technology poses no excess risk of multiple sclerosis
01 Jan 2023
Neutrophil-to-lymphocyte ratio predicts ischaemic stroke in Chinese T2DM patients
Neutrophil-to-lymphocyte ratio (NLR) is a significant predictor of new-onset ischaemic stroke in Chinese patients with type 2 diabetes mellitus (T2DM), the population-based Hong Kong Diabetes Study has shown.
Neutrophil-to-lymphocyte ratio predicts ischaemic stroke in Chinese T2DM patients
29 Dec 2022
Sovateltide: A new option to improve neuro outcomes after cerebral ischaemic stroke?
The endothelin-B receptor agonist sovateltide appears to improve neurological outcomes in patients with acute cerebral ischaemic stroke (ACIS), according to a phase III trial presented at WSC 2022.
Sovateltide: A new option to improve neuro outcomes after cerebral ischaemic stroke?
26 Dec 2022
Psychological distress contributes to increased dementia risk
Individuals with symptoms of psychological distress are at increased risk of all-cause dementia, although this association is attenuated by the competing risk of death, according to a study.
Psychological distress contributes to increased dementia risk
23 Dec 2022
HF meds rapid up-titration reduces readmission, mortality after acute HF hospitalization
Rapidly maximizing medications in patients discharged from hospital following acute heart failure (AHF) reduced the risk of hospital readmission or death at 180 days, according to results of the STRONG-HF* trial presented at AHA 2022.
HF meds rapid up-titration reduces readmission, mortality after acute HF hospitalization
21 Dec 2022
Study reinforces guideline to avoid prescribing EIASMs in glioma patients with epilepsy
First-line monotherapy with levetiracetam appears to have a more favourable effectiveness than enzyme-inducing antiseizure medications (EIASMs) in glioma patients with epilepsy, owing to lower treatment failure for any reason and better tolerability, according to a study, which supports the current neuro-oncology recommendations to avoid EIASMs in this population.
